


**Amendments to the Claims:**

This listing of claims replaces all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A compound represented by Formula I:



I

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

Ar is phenyl or naphthyl;

m = 0 or 1;

n = 0 or 1;

A is selected from the group consisting of: ~~-CO<sub>2</sub>H, -PO<sub>3</sub>H<sub>2</sub>, -PO<sub>2</sub>H, -SO<sub>3</sub>H, -PO(C<sub>1-3</sub>alkyl)OH and 1H-tetrazol-5-yl;~~

R<sup>1</sup> and R<sup>2</sup> are each independently selected from the group consisting of: hydrogen, ~~halo,~~ hydroxy, ~~-CO<sub>2</sub>H and C<sub>1-4</sub>alkyl, optionally substituted from one up to the maximum number of substitutable positions with halo;~~

R<sup>3</sup> is selected from the group consisting of: hydrogen and C<sub>1-4</sub>alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;

each R<sup>4</sup> is independently selected from the group consisting of: halo, C<sub>1-4</sub>alkyl and C<sub>1-3</sub>alkoxy, said C<sub>1-4</sub>alkyl and C<sub>1-3</sub>alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo,


C is selected from the group consisting of:

- (1) ~~C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkoxy, (C=O)-C<sub>1-6</sub>alkyl or -CHOH-C<sub>1-6</sub>alkyl, said C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkoxy, (C=O)-C<sub>1-6</sub>alkyl and -CHOH-C<sub>1-6</sub>alkyl optionally substituted with phenyl, and~~
- (2) ~~phenyl or HET, wherein HET is thienyl, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl[[,]] and C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy, said C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C<sub>1-4</sub>alkyl, optionally substituted with 1-3 halo groups,~~

or C is not present; and

~~when C is not present then B is selected from the group consisting of: phenyl, C<sub>5-16</sub>alkyl, C<sub>5-16</sub>alkenyl, C<sub>5-16</sub>alkynyl, -CHOH-C<sub>4-15</sub>alkyl, -CHOH-C<sub>4-15</sub>alkenyl, -CHOH-C<sub>4-15</sub>alkynyl, C<sub>4-15</sub>alkoxy, -O-C<sub>4-15</sub>alkenyl, -O-C<sub>4-15</sub>alkynyl, C<sub>4-15</sub>alkylthio, -S-C<sub>4-15</sub>alkenyl, -S-C<sub>4-15</sub>alkynyl, -CH<sub>2</sub>-C<sub>3-14</sub>alkoxy, -CH<sub>2</sub>-O-C<sub>3-14</sub>alkenyl, -CH<sub>2</sub>-O-C<sub>3-14</sub>alkynyl, (C=O)-C<sub>4-15</sub>alkyl, (C=O)-C<sub>4-15</sub>alkenyl, (C=O)-C<sub>4-15</sub>alkynyl, (C=O)-O-C<sub>3-14</sub>alkyl, (C=O)-O-C<sub>3-14</sub>alkenyl, (C=O)-O-C<sub>3-14</sub>alkynyl, (C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>3-14</sub>alkyl, (C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>3-14</sub>alkenyl, (C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>3-14</sub>alkynyl, N(R<sup>6</sup>)(R<sup>7</sup>)-(C=O)-C<sub>3-14</sub>alkyl, N(R<sup>6</sup>)(R<sup>7</sup>)-(C=O)-C<sub>3-14</sub>alkenyl and N(R<sup>6</sup>)(R<sup>7</sup>)-(C=O)-C<sub>3-14</sub>alkynyl,~~

~~when C is phenyl or HET then B is selected from the group consisting of: C<sub>1-6</sub>alkyl, C<sub>1-5</sub>alkoxy, (C=O)-C<sub>1-5</sub>alkyl, (C=O)-O-C<sub>1-4</sub>alkyl, (C=O)-N(R<sup>6</sup>)(R<sup>7</sup>)-C<sub>1-4</sub>alkyl,~~



when ~~C~~ is ~~C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkoxy, (C=O)-C<sub>1-6</sub>alkyl or -CHOH-C<sub>1-6</sub>alkyl~~ then ~~B~~ is ~~phenyl~~; and

~~R<sup>6</sup> and R<sup>7</sup> are independently selected from the group consisting of: hydrogen, C<sub>1-9</sub>alkyl and (CH<sub>2</sub>)<sub>p</sub>-phenyl, wherein p is 1 to 5 and phenyl is optionally substituted with 1-3 substituents independently selected from the group consisting of: C<sub>1-3</sub>alkyl and C<sub>1-3</sub>alkoxy, each optionally substituted with 1-3 halo groups.~~

2. (currently amended) The compound according to Claim 1 wherein:

~~Ar~~ is phenyl;

the group ~~-B-C~~ is attached to the phenyl ring at the 3- or 4-position;

~~C~~ is phenyl or HET, each optionally substituted with 1-3 substituents independently selected from the group consisting of: halo, phenyl, C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy, said C<sub>1-4</sub>alkyl and C<sub>1-4</sub>alkoxy groups optionally substituted from one up to the maximum number of substitutable positions with a substituent independently selected from halo and hydroxy, and said phenyl optionally substituted with 1 to 5 groups independently selected from the group consisting of: halo and C<sub>1-4</sub>alkyl, optionally substituted with 1-3 halo groups,

or ~~C~~ is not present;

when ~~C~~ is not present then ~~B~~ is selected from the group consisting of: C<sub>7-12</sub>alkyl, C<sub>7-12</sub>alkenyl, C<sub>7-12</sub>alkynyl, C<sub>6-11</sub>alkoxy, -O-C<sub>6-11</sub>alkenyl, -O-C<sub>6-11</sub>alkynyl, (C=O)-C<sub>6-11</sub>alkyl, (C=O)-

~~C<sub>6-11</sub>alkenyl, (C=O) C<sub>6-11</sub>alkynyl, (C=O) O C<sub>5-10</sub>alkyl, (C=O) O C<sub>5-10</sub>alkenyl, and (C=O) O C<sub>5-10</sub>alkynyl and C is not present;~~

and

~~when C is phenyl or HET then B is selected from the group consisting of C<sub>1-5</sub>alkyl, C<sub>1-4</sub>alkoxy, (C=O) C<sub>1-4</sub>alkyl, (C=O) O C<sub>1-3</sub>alkyl, phenyl and HET.~~

3. (canceled)

4. (original) The compound according to Claim 1 wherein m is 0.

5. (original) The compound according to Claim 1 wherein m is 1.

6. (original) The compound according to Claim 1 wherein n is 0.

7. (original) The compound according to Claim 1 wherein n is 1.

8. (canceled)

9. (currently amended) The compound according to Claim 1 wherein:

B is methoxy and C is HET, wherein said HET is thienyl substituted with phenyl and C<sub>1-4</sub>alkyl, said C<sub>1-4</sub>alkyl optionally substituted from one up to the maximum number of substitutable positions with halo, ~~and said phenyl, optionally substituted with 1 to 5 substituents independently selected from the group consisting of: halo and C<sub>1-4</sub>alkyl, optionally substituted with 1-3 halo groups.~~


10 to 20. (canceled)

21. (currently amended) The compound according to Claim ~~20~~ 4 wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are hydrogen.

22. (original) The compound according to Claim 2 wherein the group –B-C is attached to the phenyl ring at the 4-position.

23. (canceled)

24. (original) A compound represented by Formula II



II

or a pharmaceutically acceptable salt or hydrate thereof, wherein:

$n = 0$  or  $1$ ;

$R^3$  is selected from the group consisting of: hydrogen and  $C_{1-4}$ alkyl, optionally substituted with from one up to the maximum number of substitutable positions with a substituent independently selected from the group consisting of: halo and hydroxy;







each  $R^4$  is independently selected from the group consisting of: halo,  $C_{1-4}$ alkyl and  $C_{1-3}$ alkoxy, said  $C_{1-4}$ alkyl and  $C_{1-3}$ alkoxy optionally substituted from one up to the maximum number of substitutable positions with halo.


25. (original) The compound according to Claim 24 wherein  $n$  is  $0$ .

26. (original) The compound according to Claim 24 wherein  $n$  is  $1$ .

27. (original) The compound according to Claim 24 wherein R<sup>3</sup> is hydrogen.

28. (currently amended) The compound according to Claim 24 selected from the following table:



or a pharmaceutically acceptable salt of any of the foregoing compounds.

29 to 33. (canceled)

34. (original) A method of treating an immunoregulatory abnormality in a mammalian patient in need of such treatment comprising administering to said patient a compound in accordance with Claim 1 in an amount that is effective for treating said immunoregulatory abnormality.

35 to 47. (canceled)